Key result
Intracoronary anti-miR-452-5p safely improves cardiac remodeling and hemodynamics in swine cardiomyopathy.
Why the study?
The underlying mechanisms of heart failure in cardiovascular-kidney-metabolic syndrome (CKM) remain unknown, and the role of micro-RNAs in the development of CKM-induced heart failure has not been investigated.
Does a single intracoronary administration of anti-miR-452-5p improve cardiac remodeling, function, and TIMP2 signaling in a swine model of cardiovascular-kidney-metabolic syndrome?
Does a single intracoronary administration of anti-miR-452-5p improve cardiac remodeling, function, and TIMP2 signaling in a swine model of cardiovascular-kidney-metabolic syndrome?
Identifies the miR-452-5p/TIMP2/MMP-2 pathway as a novel mechanism and potential therapeutic target to prevent cardiac remodeling and heart failure in a preclinical swine model of cardiovascular-kidney-metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for miR-452-5p-targeted therapy in CKM syndrome; does not support practice change.
Background Cardiovascular-kidney-metabolic syndrome (CKM) is a systemic disorder driven by the interplay between metabolic dysfunction, chronic kidney disease, and cardiovascular disease (CVD). Heart failure (HF) is a major factor for the progression and severity of CKM, but the underlying mechanisms remain unknown. Micro-RNAs (miRNAs) have been implicated in the pathophysiology of CVD, but their role in the development of CKM-induced HF has not been investigated Methods We developed a novel swine model of CKM (bilateral renovascular disease + atherogenic diet) that recapitulates human CKM. Renal (multi-detector CT, histology) and cardiac morphology and function (echocardiography) were quantified *in vivo in* CKM and normal pigs after 14 weeks *.* Unbiased cardiac miRNA-seq identified miR-452-5p as the top miRNA upregulated in CKM vs normal. This miRNA targets tissue inhibitor of metalloproteinase *(TIMP2),* a key regulator of matrix MP (MMP)-2 and cardiac remodeling. Then, we assessed its potential as a therapeutic target in a group of CKM pigs treated with a single intracoronary (IC) administration of anti-miR-452-5p. Effects on cardiac remodeling, function, and TIMP2 signaling were quantified 4 weeks later Results We showed that miR-452-5p is largely expressed in CKM cardiomyocytes and directly targets *TIMP2* , and its overexpression *in vitro* in pig cardiomyocytes altered *TIMP2-* MMP-2 signaling and induced cardiomyocyte injury ( Fig.1 ). Notably, cardiac inhibition of miR-452-5p in CKM pigs *in vivo* safely and efficiently improved cardiac remodeling, titin degradation, and cardiac hemodynamics ( Fig.2 ) Conclusion We identified a new target and mechanism of cardiac remodeling leading to HF in CKM. More importantly, our study mechanistically supports the safety and efficacy of a new translational therapeutic strategy to protect the heart, potentially ameliorating the development of HF and the progression of CKM syndrome
No takes yet. Share an insight, caveat, or question.
Eirin et al. (2026) studied Cardiovascular-kidney-metabolic syndrome (CKM) and cardiac remodeling / heart failure. Intracoronary (IC) administration of anti-miR-452-5p vs. Untreated CKM pigs and normal control pigs was evaluated on Cardiac remodeling, function, titin degradation, cardiac hemodynamics, and TIMP2 signaling. Single intracoronary anti-miR-452-5p administration in CKM pigs safely improved cardiac remodeling, titin degradation, and cardiac hemodynamics 4 weeks after treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: